The hERG K+ channel: target and antitarget strategies in drug development.

@article{Raschi2008TheHK,
  title={The hERG K+ channel: target and antitarget strategies in drug development.},
  author={Emanuel Raschi and Valentina Vasina and Elisabetta Poluzzi and Fabrizio De Ponti},
  journal={Pharmacological research},
  year={2008},
  volume={57 3},
  pages={181-95}
}
The human ether-à-go-go related gene (hERG) K+ channel is of great interest for both basic researchers and clinicians because its blockade by drugs can lead to QT prolongation, which is a risk factor for torsades de pointes, a potentially life-threatening arrhythmia. A growing list of agents with "QT liability" have been withdrawn from the market or restricted in their use, whereas others did not even receive regulatory approval for this reason. Thus, hERG K+ channels have become a primary… CONTINUE READING
41 Citations
164 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 164 references

Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs

  • AE Lacerda, J Kramer, KZ Shen, D Thomas, AM. Brown
  • Eur Heart J Suppl 2001;3:K23–30
  • 2001
Highly Influential
20 Excerpts

Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs

  • I Cavero, J. Crumb-WJ
  • Eur Heart J Suppl 2001;3:K53–63
  • 2001
Highly Influential
20 Excerpts

Similar Papers

Loading similar papers…